Merck, Bionomics team up to develop chronic pain drug

Bionomics and Merck & Co. agreed to collaborate in the discovery and development of novel small molecule candidates for treatment of neuropathic pain and other forms of chronic pain using the latter's ionX drug discovery technology and MultiCore chemistry. The deal grants Merck an option for an exclusive license for one compound. Bionomics could get as much as $172 million in option exercise fees and milestone payments plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA